Journal Publication – Nalburiye Dergisi http://nalburiyedergisi.com/ Tue, 28 Jun 2022 19:50:26 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://nalburiyedergisi.com/wp-content/uploads/2021/07/icon-1.png Journal Publication – Nalburiye Dergisi http://nalburiyedergisi.com/ 32 32 Huawei official hails Biden administration’s cybersecurity efforts https://nalburiyedergisi.com/huawei-official-hails-biden-administrations-cybersecurity-efforts/ Tue, 28 Jun 2022 18:08:51 +0000 https://nalburiyedergisi.com/huawei-official-hails-biden-administrations-cybersecurity-efforts/ Huawei’s new charm offensive to win over skeptics in the free world includes a new target: the media. The Chinese telecom giant on Tuesday sponsored an event with the Wall Street Journal on “security and safety in an unstable world” after previously accusing the US newspaper of anti-Huawei bias and lack of credibility. Representatives for […]]]>

Huawei’s new charm offensive to win over skeptics in the free world includes a new target: the media.

The Chinese telecom giant on Tuesday sponsored an event with the Wall Street Journal on “security and safety in an unstable world” after previously accusing the US newspaper of anti-Huawei bias and lack of credibility.

Representatives for Huawei and the Journal’s publisher, Dow Jones, did not explain how the relationship turned from hostile to friendly during the event. The virtual discussion included a disclaimer that the Journal’s newsroom was not involved in the planning of the event.

Former Journal editorial board member Mary Kissel strongly criticized her former employer’s decision to partner with the Chinese company seen by many as a workhorse for the communist regime.

“So America’s leading trade publication is making dollars from the surveillance arm of a genocidal, totalitarian state,” Ms Kissel said on Twitter last week. “Perhaps legal but certainly not moral. Appalling, really.

Ms. Kissel served in the Trump administration which sought to curtail Huawei’s U.S. footprint, and the editorial board is not part of the Journal’s newsroom.


SEE ALSO: British officials say Russian forces ‘hollowed out’ Ukraine invasion casualties


The Journal’s 2020 reporting of US officials claiming Huawei had the ability to access alleged backdoors in mobile phone networks prompted the Chinese company to accuse the Journal of bias and amplifying lies.

At Tuesday’s virtual event, Andy Purdy, chief security officer of Huawei Technologies USA, answered questions from Willem Marx, editor-in-chief of the Dow Jones Global Business Council, with no trace of lingering resentment.

Mr. Marx asked Mr. Purdy to assess the efforts of the US government and others on cybersecurity and privacy risks, and Mr. Purdy responded by praising the Biden administration.

“Particularly in the areas of cybersecurity, I think there’s been increased interest and attention and a very strong public-private partnership over the past couple of years,” Purdy said. “It takes time to make these things happen. I think they were helped somewhat by President Biden’s executive order on cybersecurity nearly a year and a half ago.

Huawei has increased its lobbying efforts during President Biden’s tenure, especially in relation to former President Trump’s tenure.

Huawei spent nearly $4.5 million on lobbying during Mr. Biden’s first two years in office, according to the Center for Responsive Politics’ OpenSecrets.org database.

Huawei spent just $3.68 million during Mr. Trump’s four years in office, with the majority of lobbying taking place in 2019. Mr. Trump issued an executive order in 2019 that effectively blocked Huawei from networks American communications.

Officials from Huawei and the Journal’s publisher did not immediately respond to requests for comment on the cost of Huawei’s sponsorship and Huawei’s past criticism of the Journal. Mr. Marx and Mr. Purdy also ignored a question about the companies’ relationship at Tuesday’s event.

]]>
Edmonton councilor Janz questioned by Integrity Commissioner over tweet https://nalburiyedergisi.com/edmonton-councilor-janz-questioned-by-integrity-commissioner-over-tweet/ Mon, 27 Jun 2022 01:40:27 +0000 https://nalburiyedergisi.com/edmonton-councilor-janz-questioned-by-integrity-commissioner-over-tweet/ Breadcrumb Links Local News Ward papastew Earl. Michael Janz. Photo by David Bloom /Postmedia, file Content of the article Edmonton’s Integrity Commissioner is investigating a formal complaint against the city councillor. Michael Janz on his conduct on Twitter. Advertisement 2 This ad has not loaded yet, but your article continues below. Content of the article […]]]>

Content of the article

Edmonton’s Integrity Commissioner is investigating a formal complaint against the city councillor. Michael Janz on his conduct on Twitter.

Advertisement 2

Content of the article

The investigation stems from a tweet referring to a police officer as a “pig”, not written by Janz, but allegedly retweeted. The complaint, obtained by Postmedia, alleges a violation of the Code of Conduct policy requiring councillors’ communications, including on social media, to be “respectful and not discriminatory, harassing or abusive.” disrespect to anyone” and that communications are not misleading.

Thomas Deak, who initiated the review, told Edmonton City Integrity Commissioner Jamie Pytel that Janz “appreciated and supported the comment calling the police officers ‘pigs.'”

“Mr. Janz has an open agenda of hatred toward the Edmonton Police Department. This is clearly evident in his Twitter posts,” the complaint states.

Advertisement 3

Content of the article

A screenshot of the retweet submitted with the complaint shows a post by the Calgary account @coldbike on May 29, 2022 stating: “So this week a co-worker was ticketed $409 for not stopping his bike at a stop sign. It was 7am in a residential area, the roads were deserted except for the pig hiding in the bushes. The person who hit me with their car got a $47 ticket for not reporting. Seems fair.” At the time of publication, the tweet was not available on Janz’s account.

Pytel did not respond to a request for comment.

A screenshot provided to Postmedia shows a retweet purportedly from Ward papastew adviser Michael Janz.  The original tweet refers to a police officer as a
A screenshot provided to Postmedia shows a retweet purportedly from Ward papastew adviser Michael Janz. The original tweet refers to a police officer as a “pig”. Janz is being investigated for violating the council’s code of conduct by the city’s integrity commissioner. (Screenshot)

In an email sent Thursday and shared with Postmedia, Pytel told the complainant that the concerns were being investigated. Additional social media posts submitted with the tweet are not part of her investigation, she said.

“I have now opened a confidential investigation into your complaint dated May 30, 2022,” she wrote in the email shared with Postmedia. “I have included in the Disclosure to Counselor the image you provided of the retweeted post in question which uses the word ‘pig’. I will not review or provide the Advisor with the remaining positions as I have deemed them to be irrelevant or involve third parties who may not wish to be part of this process. »

Advertisement 4

Content of the article

Janz said he was aware of the complaint but would not comment further.

Asked about the Edmonton Police Association chief’s earlier complaint, which was dismissed by Pytel in February, Ward papastew’s adviser said he believed there was a “concerted effort to try to shutting me up and falsely painting me as some sort of radical anti-cop, which couldn’t be further from the truth.

Janz said he had friends and family in law enforcement who knew his views.

“It’s about a few people who don’t like scrutiny of their budget or their conduct and that manifests itself in hostility towards anyone who dares to question it,” he told Postmedia. “I continue to have the utmost respect for individuals, but I believe that no institution should be unchecked.”

Advertisement 5

Content of the article

Janz alleged that “fake accounts” on Twitter were seeking complaints against him. He wonders if handling what he calls “vexatious complaints” is a good use of City resources.

“I think at some point if the code of conduct is being misused, it’s time as advice that we need to review and be more specific about what exactly the code of conduct is intended to do. “, did he declare. “It is not intended to limit political speech or an elected official’s freedom of expression.”

The city council considered a potential social media policy in February 2021, but unanimously rejected it. The proposed rules would have prevented councilors from blocking voters. This discussion came after former councilor Mike Nickel was investigated for his conduct on social media.

Nickel was eventually found guilty of violating the code of conduct, but was not reprimanded.

lboothby@postmedia.com

@laurby

Advertisement 1

comments

Postmedia is committed to maintaining a lively yet civil discussion forum and encourages all readers to share their views on our articles. Comments can take up to an hour to be moderated before appearing on the site. We ask that you keep your comments relevant and respectful. We have enabled email notifications. You will now receive an email if you receive a reply to your comment, if there is an update to a comment thread you follow, or if a user follows you comments. Visit our Community Rules for more information and details on how to adjust your E-mail settings.

]]> Immunic Announces Publication – GuruFocus.com https://nalburiyedergisi.com/immunic-announces-publication-gurufocus-com/ Sat, 25 Jun 2022 10:54:34 +0000 https://nalburiyedergisi.com/immunic-announces-publication-gurufocus-com/ NEW YORK, June 15, 2022 /PRNewswire/ — immuneInc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that data from its EMPhASIS Phase 2 trial of lead asset, vidofludimus calcium (IMU-838), in patients with relapsed remitting multiple sclerosis (RRMS), was […]]]>

NEW YORK, June 15, 2022 /PRNewswire/ — immuneInc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that data from its EMPhASIS Phase 2 trial of lead asset, vidofludimus calcium (IMU-838), in patients with relapsed remitting multiple sclerosis (RRMS), was published in the peer-reviewed journal, Annals of Clinical and Translational Neurology.

The article, written by the coordinating investigator, Robert J. FoxMD, Staff Neurologist, Mellen Center for Multiple Sclerosis, Vice President of Research, Neurologic Institute, Cleveland Clinic, Cleveland, Ohiois titled, “Safety and efficacy of vidofludimus calcium, a selective dihydroorotate dehydrogenase inhibitor, in relapsing-remitting multiple sclerosis (EMPhASIS): a double-blind, randomized, placebo-controlled phase 2 trial. It is accessible via the following link: https://onlinelibrary.wiley.com/doi/10.1002/acn3.51574.

Vidofludimus calcium is a novel second-generation selective dihydroorotate dehydrogenase (DHODH) inhibitor with no off-target effects on kinases seen with drugs in the same class, which may lead to an improved safety and tolerability profile. Inhibition of DHODH has been shown to suppress magnetic resonance imaging (MRI) brain damage and disease activity in multiple sclerosis. The article assessed safety and potency on MRI-based endpoints as well as clinical and biomarker assessments of vidofludimus calcium in patients with RRMS.

“The results of this Phase 2 trial of vidofludimus calcium in patients with RRMS are encouraging, as the trial met its key primary and secondary endpoints for suppression of imaging combined lesion counts. unique active magnetic resonance scans,” said Dr. Fox. “Importantly, vidofludimus calcium was shown to be safe and well tolerated compared to placebo, with no increased rate of infections, effects on liver or blood cell laboratory parameters and with a very low treatment drop-out rate. Dr. Fox receives consulting fees for his advisory work with Immunic.

“The publication of the EMPhASIS trial results in a peer-reviewed journal demonstrates the importance of our Phase 2 findings for vidofludimus calcium in patients with RRMS,” said Daniel Vitt, Ph.D., CEO and President of Immunic. “Based on these strong data, we enrolled patients in our Phase 2 CALLIPER trial in patients with progressive multiple sclerosis to further explore the neuroprotective potential of vidofludimus calcium, as evidenced by the slowing of cerebral atrophy and delayed worsening of disability, which are often caused by axonal diseases and neural damage Equally exciting, we have also enrolled patients in our ENSURE Phase 3 program of vidofludimus calcium as a treatment relapsing multiple sclerosis (MS). We remain very excited about the potential of this new treatment to become a best-in-class DHODH inhibitor – in the RMS.”

Full plain data from the Phase 2 double-blind, placebo-controlled EMPhASIS trial (cohort 1 with 30 and 45 mg vidofludimus calcium or placebo once daily) was reported by Immunic in September 2020 and is summarized in more detail in this peer-reviewed journal. The trial met all key primary and secondary endpoints. In particular, the study met its primary endpoint, demonstrating a statistically significant reduction in the cumulative number of unique active combined MRI lesions (AUC) through week 24 in patients receiving 45 mg of vidofludimus calcium once daily. day, by 62% (p = 0.0002), compared to the placebo. The study also met its key secondary endpoint, showing a statistically significant reduction in cumulative AUC MRI lesion count for the 30 mg once daily dose by 70% (p<0.0001), compared to placebo. The data set also confirms that vidofludimus calcium was very well tolerated, in general, and that its safety profile was similar to that of the placebo group.

Earlier in 2022, Immunic published data from a second lower dose cohort of the EMPhASIS trial in RRMS (cohort 2: 10 mg vidofludimus calcium or placebo once daily) that Immunic has l intend to summarize in a future publication. In the final Cohort 2 dataset, the anti-inflammatory effects of vidofludimus calcium at a dose of 10 mg were observed to be weaker (13% reduction in gadolinium-enhancing magnetic resonance imaging lesions up to at 24 weeks, versus placebo) than those found with the 30 mg dose of vidofludimus calcium in the pooled data from Cohorts 1 and 2 (78% reduction), providing further support for dose selection of 30 mg in the ongoing ENSURE trials in the RMS.

About Vidofludimus Calcium (IMU-838)

Vidofludimus Calcium is an investigational drug in development as a next-generation, orally available, selective immune modulator designed to inhibit the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase (DHODH). Vidofludimus calcium has been observed to act on activated T and B cells while leaving other immune cells largely unchanged and allowing the immune system to continue to function, for example to fight infections. In previous trials, vidofludimus calcium did not show an increased rate of infections compared to placebo. Additionally, DHODH inhibitors, such as vidofludimus calcium, are known to possess a host-based antiviral effect, which is independent of specific viral proteins and their structure. Therefore, DHODH inhibition may be broadly applicable against several viruses. To date, vidofludimus calcium has been tested in over 1,100 people and has shown an attractive pharmacokinetic, safety and tolerability profile. Vidofludimus calcium is not yet licensed or approved in any country.

About Immunic, Inc.

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, vidofludimus calcium (IMU-838), a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the DHODH enzyme and exhibits an antiviral effect host-based, is currently being developed as a treatment option for multiple sclerosis and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγ/RORγt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of gut barrier function, is targeted for development in diseases involving gut barrier dysfunction. For more information, please visit: www.imux.com.

Caution Regarding Forward-Looking Statements

This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial condition, future revenues, projected expenses, timing and expected results of clinical trials, outlook, plans and objectives of management are forward-looking statements . Examples of such statements include, but are not limited to, statements relating to Immunic’s three development programs and target diseases; the potential of vidofludimus calcium to target disease safely and effectively; preclinical and clinical data for vidofludimus calcium; the schedule of current and future clinical trials and anticipated clinical milestones; the nature, strategy and direction of the business and other updates thereto; and the development and commercial potential of any of the Company’s product candidates. Immunic may not actually achieve the plans, achieve the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on such forward-looking statements. These statements are based on management’s current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements due to numerous factors, including, but not limited to, the COVID-19 pandemic, risks and uncertainties associated with the ability to project the use future liquidity and reserves necessary for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of preclinical studies and prior clinical trials may not not be predictive of future clinical trial results, the protection and market exclusivity provided by Immunic’s intellectual property, the risks associated with the drug development and regulatory approval process, and the impact of competing products and technological changes. A list and additional descriptions of these risks, uncertainties and other factors can be found in the section titled “Risk Factors” of the Company’s Annual Report on Form 10-K for the fiscal year ended. December 31, 2021filed with the SEC on February 24, 2022, and in the company’s subsequent filings with the Securities and Exchange Commission. Copies of these documents are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statements made in this release speak only as of the date of this release. Immunic disclaims any intention or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims any liability for actions taken or not taken based on any or all of the content of this press release.

Contact information

Immunic, Inc.
Jessica Breu
Head of Investor Relations and Communication
+49 89 2080 477 09
[email protected]

US IR contact
Rx Communications Group
Paula Schwartz
+1 917 322 2216
[email protected]

Contact with the media in the United States
KOGS communication
Edna Kaplan
+1 781 639 1910
[email protected]

favicon.png?sn=NY89175&sd=2022-06-15 Show original content to download multimedia:https://www.prnewswire.com/news-releases/immunic-announces-publication-of-data-from-its-phase-2-emphasis-trial-of-vidofludimus-calcium-in-relapsing-remitting-multiple- sclerosis-in-peer-reviewed-journal-annals-of-clinical-and-translational-neurology-301568317.html

SOURCE Immunic, Inc.

]]>
Estonian research funding still based on Soviet-era foreign relations | New https://nalburiyedergisi.com/estonian-research-funding-still-based-on-soviet-era-foreign-relations-new/ Thu, 23 Jun 2022 06:00:00 +0000 https://nalburiyedergisi.com/estonian-research-funding-still-based-on-soviet-era-foreign-relations-new/ “I have shown in my work that while research funding institutions have formally changed, the standards to which they adhere have not changed so much,” says Teele Tõnismann, researcher in political science and public administration at the University of Toulouse and TalTech. , which analyzed the research funding programs that took place in Estonia, Latvia […]]]>

“I have shown in my work that while research funding institutions have formally changed, the standards to which they adhere have not changed so much,” says Teele Tõnismann, researcher in political science and public administration at the University of Toulouse and TalTech. , which analyzed the research funding programs that took place in Estonia, Latvia and Lithuania between 1988 and the mid-2010s.

In recent decades, many governments have tried to allocate research funds based on international scientific excellence. In her recently defended doctoral thesis, Tõnismann investigated the introduction of competitive and excellence-based funding in the social sciences and humanities in the Baltic region. Her theoretical work is complemented by in-depth analyzes of interviews she conducted with policy makers and sociologists.

Tõnismann’s research revealed that the reorganization of science funding in Estonia did not follow a single EU-centric policy imposed from outside, but was imposed through power struggles between local actors. policy-making and was influenced by the international connections and bilateral relationships that scholars had already established at that time.

This means that the introduction of a competitive funding system in the social sciences and humanities occurred here mainly due to the prior international orientation of local scientific elites, who were mostly from the field of exact sciences.

New in form, but the content has remained the same

Tõnismann says that the main source of funding for research in the Soviet Union was the Academy of Sciences or industry. “It could vary depending on the location of the research groups and the links the managers had developed with outside industries.”

The political turmoil that accompanied the collapse of the Soviet Union had a profound effect on the scientific environment: “Funding from Moscow came to a halt, previously flourishing industries collapsed, and research budgets were reduced or eliminated.

It was then that the Baltic scientific communities came into action to claim their autonomy and free themselves from political control. According to Tõnismann, of the three Baltic states, Estonia, compared to Latvia and Lithuania, has been the fastest to adapt to international standards, both in terms of public funding and competitive project grants.

“In my thesis, I showed that at the level of policy-making, norms of internationalization and competitiveness were introduced by groups of people with already established international ties,” says Tõnismann. “In other words, change has only been brought about by those who have themselves already been exposed to the structure of international research funding through their studies and work, and who have then brought these principles home. .”

“The transition was smoothest in Estonia because scientists here traveled frequently also in Soviet times. For different reasons, this was not the case for Latvian and Lithuanian scientists,” explains the researcher. The Estonian Academy of Sciences and Communist Party leaders endorsed international communication, especially in the field of exact sciences, says Tõnismann, and so there were many innovation-oriented people in Estonia, who were willing and capable of introducing the new standards already in the early 1990s.

However, this transformation was partly only formal.

In the early 1990s, national research funding councils were established in Latvia and Estonia. “However, these councils awarded small grants to large numbers of individual researchers, while only a few of the larger projects qualified for international peer review practices,” says Tõnismann, pointing to stagnation. funding practices in new institutions.

For example, in 1995, the Estonian Research Council (ETF) awarded €2.88 million in grants to 883 projects out of 1,211 proposals submitted, which means that two-thirds of the projects received a grant.

“Targeted” or project-based funding has become the only viable option for researchers in Estonia and has lost its original meaning of additional funding for top-level research. “Despite the fact that we are talking about the transition to a market economy, and despite the fact that our institutional structures have changed accordingly, the regulation of research funding has not followed this transformation so quickly”, concludes Tõnismann.

If many publications are expected, they should be produced

While the ETF distributed small project grants to a large number of scientists, its successor, the current Estonian Research Council (ETAG), funds only a small number of scientific projects. “Researchers who have worked outside Estonia understand very well how highly competitive research funding in Estonia is.” In 2021, ETAG received a total of 335 grant applications, of which only 79, or a quarter, were funded.

Tõnismann argues that the reforms that shaped research funding policy in Estonia between 1988 and 2017 were largely designed by Estonian academic elites, mostly from the natural sciences. “In my work, I have shown that those involved in the research policy-making process are influenced by the norms established in their specific fields and by the networks they have formed during their university studies and their professional careers,” she explains. In the case of Estonia, this means bilateral cooperation with Nordic research communities, the United States and other Western European countries.

Tõnismann’s research has primarily focused on the impact of funding reforms on the social sciences and humanities sector, with a narrow focus on the work of sociologists. “I showed that they work in a pragmatic way: if publications in journals are expected, they carry them out,” she says. Many sociologists during the reorganization of financial institutions devoted themselves to teaching and work in the public sector, that is, on various applied projects. “So the actual work they do and the publishing requirements placed on them often don’t match up at all,” says the researcher.

As the success of a grant application depends on a high volume of academic publications, researchers in the social sciences and humanities select journals in which the publication processes are fast. However, in this way, researchers lose valuable time to fully concentrate on their work.

According to Tõnismann, under such conditions, sociologists opt for many different sources of funding, which necessitates changing research topics quickly.

“I showed that researchers themselves don’t see how these new regulations are supposed to improve the quality of their work,” she says.

However, the situation in Estonia is not as bad as that of neighboring Latvia and Lithuania. “In Lithuania, for example, many local academic journals have simply been listed as international journals while allowing their authors to continue publishing in their local language, which only nominally meets internationalization demands,” says Tõnismann. In Latvia, says Tõnismann, there is hardly any academic research in sociology and sociologists are mainly engaged in applied projects.

These processing pitfalls are not unique to the Baltic countries. In general, in countries with good core funding for all scientific research, project funding is a very good complement; whenever the funding structure is not stable, it is not”, says the researcher.

Pouring water into the populist’s mill

Tõnismann says that such a funding system, which hinders the development of researchers in the social sciences and humanities, has consequences.

“It is not possible for Estonian sociologists and other social scientists to consistently deal with social and governance-critical issues,” she explains, “because this type of work requires years of immersion “.

Despite the presence of strong research groups in the Baltic region, most sociologists, says Tõnismann, still depend on European and international partners for funding, methodologies and theories. This, unfortunately, adds to the unequal division of labor in the social sciences globally.

“The hybrid funding of Baltic sociologists and their publishing practices reflect not only a competitive research environment here, but also the peripheral position of sociology in national scientific funding hierarchies,” says Tõnismann. This marginalization is also evident in the composition of academic communities, she adds: “Baltic sociologists are predominantly female and have lower salaries than their colleagues in the exact and natural sciences.

Tõnismann says we should be particularly concerned about the extent to which academia can influence local politics. “We could, for example, discuss the rise of far-right political parties,” she says. “When faced with relatively weak social science communities, they can easily monopolize social discourse with their political agendas,” she says.

Given that Estonia is at the forefront internationally with its research policy reforms, says Tõnismann, we should be surprised that the assertive influence of social science on far-right public discourse is still lacking. .

Teele Tõnismann defended his doctorate. thesis “Research funding reforms in the Baltic countries: institutional heritage, internationalization and competition from 1988 to the mid-2010s” on June 13 at the University of Toulouse. Supervised by Professor Cécile Crespy from the University of Toulouse and Professor Rainer Kattel from the Tallinn University of Technology.

Follow the news of the ERR on Facebook and Twitter and never miss an update!

]]>
Can this critical step in publishing scientific research be any smoother? https://nalburiyedergisi.com/can-this-critical-step-in-publishing-scientific-research-be-any-smoother/ Mon, 20 Jun 2022 17:41:45 +0000 https://nalburiyedergisi.com/can-this-critical-step-in-publishing-scientific-research-be-any-smoother/ Democracy has been called the least worst system of government. Peer review is the least worst system for assessing the merit of scientific work. Peer review is the written evaluation of an article by other experts in the field. Although it looks like an evaluation by equals, the power imbalance created by the roles of […]]]>

Democracy has been called the least worst system of government. Peer review is the least worst system for assessing the merit of scientific work.

Peer review is the written evaluation of an article by other experts in the field. Although it looks like an evaluation by equals, the power imbalance created by the roles of reviewer and reviewer distorts the relationship and affects the tone of the review. Reviews can be condescending, demanding and mean.

It is painful to read harshly worded criticism of work that took hundreds or thousands of team hours and was submitted with hope and good faith. From our experience, we know that reviews can be accurate, strong, and make every scientific point while using helpful and encouraging language and tone.

Support exam

We are a team of editors of a Canadian open access renal journal, the Canadian Journal of Kidney Health and Disease. When we founded our journal in 2014, the supporting journal was the first of our guiding principles. Since then, we have written with support as editors, selected reviewers who write with support, and participated in trainings the next generation of Canadian kidney scientists to conduct comprehensive, rigorous and caring assessments.

Supported by a larger group of like-minded people from multiple disciplines, we recently published an editorial outlining these principles. A dozen other kidney journals have expressed support for the idea, with Opinions on nature Nephrology, NDT and Pediatric nephrology publish coordinated editorials reaffirming the principles of constructive criticism.

The long research process

Scientific articles condense a large amount of work into a structured format, usually no more than four to eight times the length of that article. The work of a paper begins with an idea that may be developed by the team for a year or more before crystallizing into a funding request, which may go through rounds of revisions.

Once funded, people and budgets are assigned to the project and the work continues. The work can involve the time of several team members for months or even years.

When the job is done, they write an article, detailing what they did, how and why, what they found, and what they think it means. This article itself is often the product of hundreds of hours of work, with multiple authors contributing their specific expertise and working on the overall message.

The journal receives the manuscript and appoints an editor, who appoints peer reviewers. Peer reviewers are other scientists working on similar topics. They must be completely independent of the people who write the journal. With a few notable exceptions, most journals use single-mask peer review: the reviewer sees the authorship of the article, but the authors of the article do not see who wrote the review.

Peer reviewers are not paid or rewarded for their review of the manuscript – they assume it as part of the work of academic life. It is essentially an unpaid activity carried out by people who are themselves authors. It varies by discipline, but in biomedicine they can spend three to six hours on an exam.

Harsh reviews

How does this altruistic activity, undertaken by a critic who knows the authorship very well, lead to so much pain and frustration for other authors?

We believe that scientists sometimes confuse harshness with intellectual rigor and that a reviewer’s experience of harshness in critiques of their own work, amplified by the power imbalance between reviewer and reviewer, leads to the perpetuation of harsh and pointless criticism. Other reviewers and editors avoid these pitfalls altogether.

“This seems to me to be one of your first attempts at scientific publishing, and I can understand that you were also writing in a non-native language” wrote an anonymous reviewer to a mid-career woman scientist with 13 peer-reviewed publications. “I just wanna quit today,” she wrote.

But she won’t. Scientists are ready to receive these kinds of comments and be hurt again and again in the name of science. As editors, we believe there is a better way – that comments should be rigorous, but will be more easily incorporated if kindly given, to the advancement of science.

These are not new ideas. In 2006, Professor Mohan Dutta suggested 10 commandments for critics, all of which emphasize the collaborative nature of the relationship between examiner and examinee. Advice to reviewers often includes a recommendation to write constructively, although this is sometimes phrased as something like “write constructively, then turn to criticism”, as if these are mutually exclusive.

We can take this principle one step further, and through our community of kidney medicine reviewers, we and other kidney journals are committed to reviewing kindness. Dutta’s 10th commandment is “do unto others as you would have them do unto you”. Every branch of science would be improved by the implementation of this idea.

]]>
Arcellx announces a release – GuruFocus.com https://nalburiyedergisi.com/arcellx-announces-a-release-gurufocus-com/ Sat, 18 Jun 2022 21:36:13 +0000 https://nalburiyedergisi.com/arcellx-announces-a-release-gurufocus-com/ 100% TRO; 75% RC/RCS; and evidence of durable clinical benefit in a population with poor prognostic features seen in dose escalation cohorts with CART-ddBCMA FOSTER CITY, Calif. , May 9, 2022 /PRNewswire/ — Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reinventing cell therapy by developing innovative immunotherapies for patients with cancer and other terminal diseases, […]]]>

100% TRO; 75% RC/RCS; and evidence of durable clinical benefit in a population with poor prognostic features seen in dose escalation cohorts with CART-ddBCMA

FOSTER CITY, Calif. , May 9, 2022 /PRNewswire/ — Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reinventing cell therapy by developing innovative immunotherapies for patients with cancer and other terminal diseases, today announced the publication of clinical data from its dose escalation cohorts in its ongoing Phase 1 study of CART-ddBCMA for the treatment of patients with relapsed or refractory multiple myeloma (r/r MM). The data was published in Blood Advancesthe open access journal of the American Society of Hematology.

The publication titled, “Phase 1 Study of CART-ddBCMA for the Treatment of Subjects With Relapsed and Refractory Multiple Myeloma,” reported the following:

  • Twelve patients in the dose escalation cohorts received a single dose of 100×106 CART-ddBCMA (DL1, n=6) or 300×106 CART-ddBCMA (DL2, n=6) following a standard lymphodepletion regimen.
  • No cases of CRS or ICANS grade 3 or higher occurred at DL1, the recommended phase 2 dose.
  • No Parkinsonian-like movement disorders or atypical neurological toxicity were observed.
  • The maximum tolerated dose was not reached.
  • All treated patients responded to CART-ddBCMA (TRO 100%) and 9/12 (75%) patients achieved CR/CRS.
  • Responses deepened over time and as data was cut (November 4, 2021; median follow-up of 56 weeks), 7/9 (78%) of evaluable patients achieved minimal residual disease negativity at 10-5 or bigger.
  • These results demonstrate the potential safety of CART-ddBCMA cells and durable responses to CART-ddBCMA in r/r MM patients.

The complete online publication is accessible here.

“We are honored to have the clinical results of the first 12 patients treated in the dose escalation cohorts with CART-ddBCMA published in a leading hematology journal,” said Rami Elghandour, Chairman and CEO of Arcellx. “Given these early results, we have expanded our Phase 1 study to the planned pivotal Phase 2 study dose of 100 million cells, and we believe these data indicate the potential for CART-ddBCMA to be an option. first-in-class treatment for patients with multiple myeloma. We look forward to presenting new clinical data at ASCO on June 5 and the initiation of our pivotal Phase 2 study for CART-ddBCMA in the second half of this year. »

About Multiple Myeloma
Multiple myeloma (MM) is a type of blood cancer in which diseased plasma cells proliferate and accumulate in the bone marrow, crowding out healthy blood cells and causing bone damage, loss of bone density and bone fractures. These abnormal plasma cells also produce excessive amounts of an abnormal immunoglobulin fragment, called myeloma protein (M protein), causing kidney damage and impairing the patient’s immune function. Multiple myeloma is the third most common hematological malignancy United States and Europe, accounting for approximately 10% of all cases of hematologic cancer and 20% of deaths from hematological malignancies. The median age of patients at diagnosis is 69 years with a third of patients diagnosed at an age of at least 75 years. Because MM tends to affect patients late in life, patients often have multiple comorbidities and toxicities that can quickly escalate and be life-threatening.

About CART-ddBCMA
CART-ddBCMA is Arcellx’s BCMA-specific CAR-modified T-cell therapy using the Company’s novel BCMA-targeting binding domain for the treatment of patients with relapsed or refractory multiple myeloma. CART-ddBCMA is currently in a Phase 1 study. Arcellx’s proprietary binding domains are novel synthetic proteins designed to bind to specific therapeutic targets. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the United States Food and Drug Administration.

About Arcellx, Inc.
Arcellx, Inc. is a clinical-stage biotechnology company reinventing cell therapy by designing innovative immunotherapies for patients with cancer and other life-threatening diseases. Arcellx believes that cell therapies are one of the advanced pillars of medicine and Arcellx’s mission is to advance humanity by developing safer, more effective and more widely available cell therapies. Arcellx’s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory multiple myeloma (r/r MM) in an ongoing Phase 1 study. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the United States Food and Drug Administration.

Arcellx is also advancing its doseable and controllable CAR-T therapy, ARC-SparX, into the clinic through two programs: ACLX-001 in r/r MM and ACLX-002 in relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Visit www.arcellx.com for more information.

Forward-looking statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements in this press release that are not purely historical are forward-looking statements, including Arcellx’s expectations regarding the timing of clinical trials for its product candidates and the communication of results thereof and beneficial characteristics potential, safety, tolerability, efficacy and therapeutic effects. of its product candidates. The forward-looking statements contained herein are based on Arcellx’s current expectations and involve assumptions which may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including those set forth in Part I, Section 1A (Risk Factors) of Arcellx’s Annual Report on Form 10- K and in other reports, including Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, which Arcellx may file from time to time with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and Arcellx undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except if required by law.

Investor contacts:
Myesha Lacy
Arcellx, Inc.
[email protected] 510-418-2412

Media Contact:
Andrea Cohen
Sam Brown Inc.
[email protected]
917-209-7163

favicon.png?sn=DC50841&sd=2022-05-09 Show original content to download multimedia:https://www.prnewswire.com/news-releases/arcellx-announces-publication-in-blood-advances-of-clinical-results-from-the-dose-escalation-cohorts-of-its-cart-ddbcma- phase-1-study-in-patients-with-relapsed-or-refractory-multiple-myeloma-301542812.html

SOURCEArcellx, Inc

]]>
Charlotte Canion will be featured in the 2nd edition of the Top 50 Fearless Leaders publication by IAOTP https://nalburiyedergisi.com/charlotte-canion-will-be-featured-in-the-2nd-edition-of-the-top-50-fearless-leaders-publication-by-iaotp/ Tue, 14 Jun 2022 19:05:12 +0000 https://nalburiyedergisi.com/charlotte-canion-will-be-featured-in-the-2nd-edition-of-the-top-50-fearless-leaders-publication-by-iaotp/ New York, NY, USA – 06/14/2022 – Charlotte Canion, author, keynote speaker, inventor and mentor, was recently selected to be featured in the 2nd edition of the International Association of Top Professionals (IAOTP) Top 50 Fearless Leaders publication. Being selected for publication in the publication of the IAOTP’s Top 50 Fearless Leaders is an honor, […]]]>

New York, NY, USA – 06/14/2022 –

Charlotte Canion, author, keynote speaker, inventor and mentor, was recently selected to be featured in the 2nd edition of the International Association of Top Professionals (IAOTP) Top 50 Fearless Leaders publication.

Being selected for publication in the publication of the IAOTP’s Top 50 Fearless Leaders is an honor, only 50 of the world’s brightest, courageous and inspiring professionals are selected for this distinction.

These special winners are carefully selected to share their stories of perseverance, resilience, passion and strength. Ms. Canion has made an outstanding contribution to society and had an incredible impact on her industry. A chapter will be dedicated to each winner and the book should be released in the 1st quarter of 2023.

Ms. Canion will be honored at the IAOTP’s 2022 Annual Awards Gala at the Bellagio Hotel in Las Vegas as a featured member of the publication’s Top 50 Fearless Leaders. She will also receive her accolades as Lifetime Achievement Winner for 2021 and Empowered Woman of the Year for 2020.

Ms. Canion has over 20 years of experience as a caregiver, and she has used her unique experiences to propel her writing career. While caring for her three aging parents, Ms Canion collected her real-life stories, which were set out in her award-winning book ‘You Must Laugh to Avoid Crying / How to Parent Your Parents’. Through this book, Ms. Canion teaches about empowering yourself by putting on the Armor of Knowledge and helping people laugh in good times and bad.

Charlotte’s impressive repertoire of published works includes a workbook called “Parenting Your Parents Journal,” which helps answer many of the questions a caregiver needs to know. Ms. Canion has a proven track record as an award-winning author and has hosted Indie Beacon radio for the past three years. During COVID Lockdown: Charlotte made over 700 masks and mailed them to other caregivers and friends across the United States. Charlotte recently won the title of Ms. Texas Senior America 2022 / 1st Runner-up and performs with the CAMEO Club at events throughout Texas.

As a Texas Super Star Master Gardener, she shares gardening tips with everyone and is passionate about teaching all gardeners, especially seniors, how to set up Keyhole Gardens and Raised Bed Gardens. This will allow residents to actively participate in the planting and harvesting of herbs and vegetables in their nursing home communities. The cuisines of these communities may use these herbs and vegetables in the food served. She has over ten Power Point presentations on many aspects of gardening. Charlotte is the inventor of the Basket Jacket, an insulating cover for hanging plants and is the author of a gardening book called “MeMom and Friends Gardening Tips”.

Ms. Canon has written numerous articles and stories for magazines and books; Angels on Earth, Denton County Magazine (Christmas – Making Memories) and is featured in “Short Stories by Texas Authors”, Texas Stories, The Art of Brave Living”, Lake Cities Magazine (Spotlight Personality) and Keller Parish Neighborhood Magazine.

Charlotte is certified by the National Speakers Association Academy and the NCSC (National Certified Senior Caregiver). She belongs to several prestigious organizations and is an active member of her church. She has served on association boards and is an active member of the Texas Authors Association, is an active host of Indie Beacon Radio, Authors Marketing Guild, National Speakers Association, DCMGA, ABWN, Continuity of Care CBA , Friends of the Library Lifetime member and active member of the Ms. Texas Senor America Cameo Club and Dementia Care volunteer.

Throughout her distinguished career, Ms. Canion has received awards, accolades and been recognized around the world for her outstanding leadership and commitment to the profession. Her authentic leadership as a business professional earned her the Empowered Woman Award from the International Association of Best Professionals. For 2021, she received the Lifetime Achievement Award from the IAOTP. In 2019, she was featured in TIP (Top Industry Professionals) magazine and was selected as Best Author of the Year by the IAOTP. In 2018, she received the Best Self Help Book award from the Texas Authors Association, was chosen as Pinnacle Professional of the Year and for the Lifetime Achievement Award by Continental Who’s Who. Ms. Canion was also awarded the Top 50 Authors You Should Read, WOW Women of Worth Award, Spirited Woman Award and CUTV Author of the Year, and first runner-up in the Ms. Texas Senior America competition. Just to name a few.

She is currently working on a new children’s book, which has been close to her heart for many years and which she wishes to dedicate to her twenty grandchildren and three great-grandchildren. “Life is never boring” around the Canion family is a quote from her husband, Crague, who is 100% supportive of her and tells her every day. His comment every morning is; “Who is the life are you going to touch today?”

Looking back, Ms. Canion attributes her success to her perseverance, work ethic and adaptability, all of which she attributes to her mother, who gave her the love, respect and patience to be the best possible, each and everyone. daytime. When not working, she enjoys traveling and spending time with her family, which includes these twenty-three grandchildren and great-grandchildren. Looking ahead, she hopes to continue to help others build and strengthen happy memories by remembering to find humor every day and especially during the otherwise difficult and overwhelming end-of-life journey.

His philosophy: “To help people laugh in good times and bad. We all get gifts and one of mine is service, my friends call me their “Go to Person” when they have a problem. God, family and friends are special gifts in my garden of life and I have four golden words that I try to live: Love – Respect – Patience – Forgiveness and when I keep them close to my heart and in my mind – I know I will have done my best. “

Watch his biography in video: https://www.youtube.com/watch?v=L6BzSrWnujA

For more information on Charlotte Canon, please visit: www.howtoparentyourparents.net

https://charlottecanionspeaks.now.site/home

Book available for purchase on Amazon.com

You have to LAUGH not to cry / How to educate your parents

Sparks – Ignite your path to success

Texas Stories by Texas Authors

Courageous lifestyle

About the IAOTP

The International Association of Top Professionals (IAOTP) is an international networking organization that selects the world’s most prestigious top professionals in different industries. These top professionals have the opportunity to collaborate, share ideas, be keynote speakers, and help influence others in their fields. This organization is not a membership that anyone can join. You must be requested by the President or be nominated by a distinguished honorary member after a brief interview.

IAOTP experts have given thousands of prestigious professionals around the world the recognition and credibility they deserve and helped build their brand empires. The IAOTP prides itself on being a one-of-a-kind networking organization that selects only the best of the best and creates a networking platform that connects and brings together these top professionals.

For more information on the IAOTP, please visit:

www.iaotp.com

Media contacts:

Company name: IAOTP
Full name: Stephanie Cirami
Phone: 212 634 4427
E-mail address: Send an email
Website: http://www.iaotp.com

For the original short story, please visit https://www.publishedpr.com/news/charlotte-canion-to-be-featured-in-the-2nd-edition-of-the-top-50-fearless-leaders-publication-by-iaotp/9187412.

]]>
Astronomers may have detected a ‘dark’ free-f https://nalburiyedergisi.com/astronomers-may-have-detected-a-dark-free-f/ Sat, 11 Jun 2022 02:01:40 +0000 https://nalburiyedergisi.com/astronomers-may-have-detected-a-dark-free-f/ image: Hubble Space Telescope image of a distant star that has been illuminated and distorted by an invisible but very compact and heavy object between it and Earth. The compact object – estimated by astronomers at UC Berkeley to be between 1.6 and 4.4 times the mass of our sun – could be a free-floating […]]]>

image: Hubble Space Telescope image of a distant star that has been illuminated and distorted by an invisible but very compact and heavy object between it and Earth. The compact object – estimated by astronomers at UC Berkeley to be between 1.6 and 4.4 times the mass of our sun – could be a free-floating black hole, one of perhaps 200 million in the Galaxy of the Milky Way.
see After

Credit: Image courtesy of STScI/NASA/ESA

If, as astronomers believe, the death of large stars leaves black holes, there should be hundreds of millions of them scattered across the Milky Way galaxy. The problem is that isolated black holes are invisible.

Now a team led by the University of California, Berkeley, astronomers have discovered what could be a free-floating black hole for the first time by observing the brightening of a more distant star as its light was distorted by the strong gravitational field of the object – therefore – called gravitational microlens.

The team, led by graduate student Casey Lam and Jessica Lu, an associate professor of astronomy at UC Berkeley, estimates the mass of the invisible compact object to be between 1.6 and 4.4 times that of the sun. Because astronomers believe the remnant of a dead star must be heavier than 2.2 solar masses to collapse into a black hole, UC Berkeley researchers warn the object could be a neutron star instead of a black hole. Neutron stars are also dense and very compact objects, but their gravity is balanced by the internal neutron pressure, which prevents further collapse into a black hole.

Whether it’s a black hole or a neutron star, the object is the first dim stellar remnant – a stellar “ghost” – discovered wandering the galaxy unassociated with another star.

“This is the first free-floating black hole or neutron star discovered with a gravitational microlens,” Lu said. “With the microlens, we are able to probe these solitary, compact objects and weigh them. I think we opened a new window on these dark objects, which cannot be seen otherwise.”

Determining how many of these compact objects populate the Milky Way galaxy will help astronomers understand the evolution of stars – in particular, how they die – and our galaxy, and perhaps reveal whether any of the invisible black holes are primordial black holes, which some cosmologists believe were produced in large quantities during the Big Bang.

The analysis by Lam, Lu and their international team has been accepted for publication in The Astrophysical Journal Letters. The analysis includes four other microlensing events that the team concluded were not caused by a black hole, although two were likely caused by a white dwarf or neutron star. The team also concluded that the probable population of black holes in the galaxy is 200 million – about what most theorists had predicted.

Same data, different conclusions

Notably, a competing team from the Space Telescope Science Institute (STScI) in Baltimore analyzed the same microlensing event and claims that the mass of the compact object is closer to 7.1 solar masses and indisputably a black hole. An article describing the analysis of the STScI team, led by Kailash Sahuhas been accepted for publication in The Astrophysical Journal.

Both teams used the same data: photometric measurements of the distant star’s illumination when its light was distorted or “lensed” by the super-compact object, and astrometric measurements of the displacement of the star’s location. distant star in sky due to gravity distortion by lens object. The photometric data comes from two microlensing surveys: the Optical Gravitational Lensing Experiment (OGLE), which uses a 1.3-meter telescope in Chile operated by the University of Warsaw, and the Microlensing Observations Experiment in Astrophysics (MOA), which is mounted on a 1.8- meter telescope in New Zealand operated by Osaka University. Astrometric data comes from NASA’s Hubble Space Telescope. STScI manages the telescope’s science program and conducts its science operations.

Since both microlensing surveys captured the same object, it has two names: MOA-2011-BLG-191 and OGLE-2011-BLG-0462, or OB110462, for short.

While surveys like these uncover around 2,000 stars lit by microlenses each year in the Milky Way galaxy, the addition of astrometric data is what allowed the two teams to determine the mass of the compact object. and its distance from Earth. The UC Berkeley-led team estimated it to be between 2,280 and 6,260 light-years (700-1920 parsecs), toward the center of the Milky Way and near the large bulge that surrounds the black hole. central mass of the galaxy.

The STScI group estimated it to be about 5,153 light-years (1,580 parsecs) away.

Looking for a needle in a haystack

Lu and Lam first became interested in the object in 2020 after the STScI team tentatively concluded that five microlens events observed by Hubble – all of which lasted over 100 days, and therefore could have been black holes – might not be caused by compact objects after all.

Lu, who has been searching for floating black holes since 2008, believed the data would help him better estimate their abundance in the galaxy, which has been estimated at between 10 million and 1 billion. To date, star-sized black holes have only been found as part of binary star systems. Black holes in binaries are visible either in X-rays, produced when material from the star falls on the black hole, or by recent gravitational wave detectors, which are sensitive to mergers of two or more black holes. But these events are rare.

“Casey and I saw the data and we got really interested. We said, “Wow, no black holes. It’s amazing,” even though there should have been,” Lu said. “And so, we started looking at the data. If there were really no black holes in the data, that would not fit our model for how many black holes there should be in the Milky Way.Something should change in our understanding of black holes – either their number, or the speed at which they move, or their mass .

When Lam analyzed the photometry and astrometry for the five microlensing events, she was surprised that one, OB110462, had the characteristics of a compact object: the lensing object appeared dim, and therefore not a star. ; the stellar brightening lasted a long time, almost 300 days; and the background star position distortion was also long lasting.

The length of the lens event was the main clue, Lam said. In 2020, she showed that the best way to search for black hole microlenses was to search for very long events. Only 1% of detectable microlensing events are likely to originate from black holes, she said, so looking at all the events would be like looking for a needle in a haystack. But, Lam calculated, about 40% of microlensing events that last longer than 120 days are likely to be black holes.

“The duration of the brightening event is an index of the mass of the foreground lens that bends the light from the background star,” Lam said. “Long events are more likely due to black holes. This is not a guarantee, however, because the duration of the brightening episode depends not only on the mass of the foreground lens, but also on the rate at which the foreground lens and the background star are moving relative to each other.However, by also obtaining measurements of the apparent position of the background star, we can confirm whether the lens of foreground is really a black hole.”

According to Lu, the gravitational influence of OB110462 on the light from the background star was surprisingly long. It took about a year for the star to peak in 2011, then about a year to return to normal.

More data will tell black hole from neutron star

To confirm that OB110462 was caused by a super-compact object, Lu and Lam requested more astrometric data from Hubble, some of which arrived last October. These new data showed that the change in position of the star resulting from the gravitational field of the lens is still observable 10 years after the event. Further Hubble observations of the microlens are tentatively scheduled for fall 2022.

Analysis of the new data confirmed that OB110462 was likely a black hole or neutron star.

Lu and Lam suspect that the two teams’ differing conclusions are due to the fact that astrometric and photometric data give different measurements of the relative motions of foreground and background objects. The astrometric analysis also differs between the two teams. The UC Berkeley-led team argues it’s not yet possible to distinguish whether the object is a black hole or a neutron star, but they hope to resolve the discrepancy with more Hubble data and analysis. improved in the future.

“While we’d like to say it’s definitely a black hole, we should point out all allowed solutions. This includes both lower-mass black holes and possibly even a neutron star,” said said Lu.

“If you can’t believe the light curve, the brightness, then that’s telling you something important. If you can’t believe the position versus time, that’s telling you something important,” Lam said. “So if one of them is wrong, we need to figure out why. Or the other possibility is that what we’re measuring in both datasets is correct, but our model is wrong. The photometry and d astrometry comes from the same physical process, which means that brightness and position must be consistent with each other, so something is missing.

The two teams also estimated the speed of the super compact lens object. The Lu/Lam team found a relatively calm speed, less than 30 kilometers per second. The STScI team found an unusually high speed, 45 km/s, which they interpreted as the result of an extra kick the alleged black hole received from the supernova that generated it.

Lu interprets his team’s low-velocity estimate as potentially supporting a new theory that black holes are not the result of supernovae – the prevailing hypothesis today – but rather originate from failed supernovae that do not bright splashes in the universe or do not give the resulting black. hole a kick.

Lu and Lam’s work is supported by the National Science Foundation (1909641) and the National Aeronautics and Space Administration (NNG16PJ26C, NASA FINESST 80NSSC21K2043).


]]>
Daily Overview: Messenger Received | Daily overview https://nalburiyedergisi.com/daily-overview-messenger-received-daily-overview/ Thu, 09 Jun 2022 00:06:12 +0000 https://nalburiyedergisi.com/daily-overview-messenger-received-daily-overview/ What has been billed as the biggest review of NHS leadership since the 1980s has recommended a single set of “basic leadership and management standards” for managers. General Sir Gordon Messenger and Dame Linda Pollard say an ‘institutional deficiency’ has formed in the way leadership and management are trained and developed in the health service. […]]]>

What has been billed as the biggest review of NHS leadership since the 1980s has recommended a single set of “basic leadership and management standards” for managers.

General Sir Gordon Messenger and Dame Linda Pollard say an ‘institutional deficiency’ has formed in the way leadership and management are trained and developed in the health service.

The report produced seven recommendations (see our full story), all of which were accepted in full by Health and Social Care Secretary Sajid Javid, who said they needed to be implemented “urgently”. .

The recommendations do not include any registration system for NHS managers, despite calls by some for many years for greater regulation of roles, nor do they appear to include specific reform of the ‘fit and proper person’ test. which has been discredited and is under review.

Asked by HSJ ahead of the publication of the report on the impact of historic underfunding on the quality of NHS management, General Sir Gordon said good leadership need not be “a hugely resource-intensive function”.

“All I would say is that good leadership and management skills among clinicians and non-clinicians is not necessarily an extremely resource-intensive function, and a lot can be achieved by approaching it from the right way.”

Also in an interview with HSJ, Javid said the health system must find ways to attract talented leaders to struggling areas.

He said, “One of [the report’s recommendations] is what I would call breaking the cycle of poor performance, which is nurturing the best talent in the toughest parts of the system with better support.

“We need to give them incentives, whether regional or other parts of the system, to move there, and provide them with better support programs…

“It can vary from looking at their compensation packages and making sure there’s enough flexibility and variability in there, but also recognition I think is a big part of that, and support for them. .”

There was some disagreement in the immediate aftermath of the report’s publication, with Sir Gordon saying that Mr Javid’s assertion that the number of NHS roles dedicated to promoting equality and diversity should be reduced is incorrect and not what the review recommended.

To clarify his position, he says HSJ“The report does not recommend the reduction of equality, diversity and inclusion professionals.

“What he’s saying though is that if you can successfully instill EDI into the responsibilities of every leadership, it becomes an accepted, instinctive, and understood part of being a leader and manager at all levels, then the need for dedicated EDI professionals should diminish over time. ”

]]>
Leadership development Books Self-publishing costs Marketing training launch https://nalburiyedergisi.com/leadership-development-books-self-publishing-costs-marketing-training-launch/ Tue, 07 Jun 2022 06:08:27 +0000 https://nalburiyedergisi.com/leadership-development-books-self-publishing-costs-marketing-training-launch/ Westport, United States – June 7, 2022 — Paper Raven Books’ upcoming book marketing webinar is for authors, publishers, and readers in the leadership and skills development niche. As the market for self-published books grows, the training program helps attendees better understand the cost of self-publishing and key publishing trends in 2022. More information can […]]]>

Paper Raven Books’ upcoming book marketing webinar is for authors, publishers, and readers in the leadership and skills development niche. As the market for self-published books grows, the training program helps attendees better understand the cost of self-publishing and key publishing trends in 2022.

More information can be found at: https://theagentofinfluence.com/bbp-free-training

Paper Raven Books and The Agent of Influence have launched the new webinar for professionals in leadership development, mentoring, strategy, motivational speaking and communication. The training presents an innovative approach to publishing success supported by the case study of a bestselling book.

The webinar will cover various case studies of successful authors who have sold over 10,000 copies of their book and list common mistakes to avoid.

Prospective authors interested in the evolution of the publishing industry since 2020 can benefit from this webinar. In addition to sharing recent changes, the webinar will also help authors identify the “right book”, next steps for publication, and how to achieve better results in social media visibility and sales without guest posting. or social media campaigns.

Whether they are in the ideation stage or already in possession of a completed manuscript, participants can benefit from these principles at any stage of their creative journey.

About Paper Raven Books

Paper Raven Books was founded by keynote speaker, author and entrepreneur Morgan Gist MacDonald who has a background in research, writing and over 15 years of experience developing best practices in digital publishing. Author nominations can be submitted here: https://theagentofinfluence.com/bbp-application

A member of staff said: “This is information no one else in the publishing world is sharing, and we believe this strategy will be what separates the next generation of successful authors from potential authors who don’t. never seem to catch a break.”

Authors unsure of which publishing route to take can find more information at https://theagentofinfluence.com/publishingpathquiz

Contact information:
Name: Kusuma Widjaja
E-mail: Send an email
Organization: the agent of influence
Address: 606 Post Road East, #559, Westport, Connecticut 06880, USA
Website: https://theagentofinfluence.com

Build ID: 89076253

If you detect any problems, problems or errors in the content of this press release, please contact [email protected] to let us know. We will respond and rectify the situation within the next 8 hours.

countex tracking

COMTEX_408308796/2773/2022-06-07T02:05:51

]]>